p38 MAPK Inhibitor Modulation of Influenza Hypercytokinemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypercytokinemia associated with severe influenza virus infection are ineffective, and existing anti-inflammatory agents either fail to provide broad anti-inflammatory effects or worsen the patient's condition, highlighting the need for a therapy that can attenuate the exaggerated inflammatory response while preserving the host's protective immune response.
Innovation Solution
A p38 MAP kinase inhibitor, specifically formulated as compounds of Formula II, is used to inhibit the release of pro-inflammatory mediators from endothelial, immune, and epithelial cells, thereby reducing the levels of cytokines such as IL-1β, IL-6, IL-8, IL-10, IP10, TNFα, RANTES, and MIP-1a, thus attenuating hypercytokinemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If existing anti-inflammatory agents (corticosteroids, aspirin, monoclonal antibodies) are used to treat hypercytokinemia, then the inflammatory response is suppressed, but the host's protective immune response is also weakened or the patient's condition worsens
Solution Approach 1:
The patent employs p38 MAP kinase inhibitors that selectively modulate the inflammatory response by targeting specific signaling pathways. This changes the parameter of inflammatory mediator production at the molecular level, allowing attenuation of harmful cytokines while preserving essential immune functions through pathway-specific inhibition rather than broad suppression
Solution Approach 2:
The p38 MAP kinase inhibitor acts as an intermediary molecule that intervenes in the signaling cascade between influenza virus infection and cytokine production. By blocking the p38 MAP kinase enzyme, it prevents the transmission of inflammatory signals while allowing other protective immune pathways to remain functional
2Quantity of substance
If broad anti-inflammatory effects are achieved through existing treatments, then cytokine levels are reduced, but the treatments fail to provide effective therapy or worsen patient outcomes
Solution Approach 1:
The p38 MAP kinase inhibitors achieve selective modulation of inflammatory mediator production by targeting the specific p38 signaling pathway. This parameter-specific approach reduces harmful cytokines (IL-6, TNF-α, IL-1β) while preserving other immune functions, thereby improving therapeutic effectiveness without the adverse effects of broad anti-inflammatory suppression
3Object-affected harmful factors
If the inflammatory response is completely suppressed to prevent damage, then hypercytokinemia is controlled, but the host's protective immune response is lost
Solution Approach 1:
The p38 MAP kinase inhibitor applies local quality by targeting specific inflammatory pathways (p38 signaling) rather than globally suppressing all immune responses. This localized intervention selectively reduces harmful inflammatory mediators while leaving other protective immune mechanisms intact, achieving differential modulation of immune function
Data Source
Figure 1
Figure 2
Figure 2
AI summary
The invention provides a p38 MAPK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof : Formula I for use in the treatment or prevention of hypercytokinemia in a human patient; wherein R is C1-3alkyl, optionally substituted by one or more halo, NR1R2 or hydroxy, and R1 and R2 are independently H, halo or C1-3alkyl, optionally substituted by one or more F. Also provided are compositions for use in the treatment or prevention of hypercytokinemia comprising the p38 MAPK inhibitor of Formula I; and methods for treating or preventing hypercytokinemia in a human patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAPK inhibitor of Formula I. The invention also provides a p38 MAPK inhibitor and an antimicrobial agent, such as an antiviral agent, for use in the treatment or prevention of hypercytokinemia.